Triclabendazole 250 MG Oral Tablet — RxCUI 2118606
RxNorm drug concept · Semantic clinical drug
RxCUI 2118606
Semantic clinical drug · SCD
● Current RxNorm concept 1 FDA product
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2118606
Official nameTriclabendazole 250 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Triclabendazole: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Fascioliasis is an infection caused by liver flukes — small parasitic flatworms called Fasciola — that can infect the liver and bile ducts. People typically get it by eating raw or...
- What exactly is fascioliasis, and how did I get it?
- Yes — taking Egaten with food really matters. A meal can increase how much of the drug your body absorbs by up to three times compared to taking it on an empty stomach. That differ...
- Do I really need to take this with food? What happens if I forget?
🕸️ Concept Web — How Triclabendazole 250 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Triclabendazole 250 MG Oral Tablet
RxCUI 2118606 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Triclabendazole
2118525IN
-
Triclabendazole
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Egaten
2118607BN
-
Egaten
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Triclabendazole Oral Tablet
2118605SCDF -
Triclabendazole Oral Product
2118603SCDG -
Triclabendazole Pill
2118604SCDG -
Triclabendazole Oral Tablet [Egaten]
2118609SBDF -
Egaten Oral Product
2118610SBDG -
Egaten Pill
2118611SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Triclabendazole Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Triclabendazole 250 MG
2118601SCDC -
Triclabendazole 250 MG Oral Tablet [Egaten]
2118612SBD -
Triclabendazole 250 MG [Egaten]
2118608SBDC
-
Triclabendazole 250 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Triclabendazole 250 MG
SCDC · 2118601 -
Triclabendazole Oral Tablet
SCDF · 2118605 -
Triclabendazole Oral Product
SCDG · 2118603 -
Triclabendazole Pill
SCDG · 2118604
Brand-Name Concepts
-
Triclabendazole 250 MG Oral Tablet [Egaten]
SBD · 2118612 -
Triclabendazole 250 MG [Egaten]
SBDC · 2118608 -
Triclabendazole Oral Tablet [Egaten]
SBDF · 2118609 -
Egaten Oral Product
SBDG · 2118610 -
Egaten Pill
SBDG · 2118611 -
Egaten
BN · 2118607
📦 FDA Products & Package NDCs
1 product · 1 package NDC
1 package NDC map to RxCUI 2118606 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00078-0937-91 | 4 TABLET in 1 BLISTER PACK (0078-0937-91) | EGATEN | Novartis Pharmaceuticals Corporation | 2019-02-13 |
Observed labelers:
Novartis Pharmaceuticals Corporation (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.